Licorice isoliquiritigenin dampens angiogenic activity via inhibition of MAPK-responsive signaling pathways leading to induction of matrix metalloproteinases

被引:56
作者
Kang, Sang-Wook [1 ,2 ]
Choi, Jung-Suk [1 ,2 ]
Choi, Yean-Jung [1 ,2 ]
Bae, Ji-Young [1 ,2 ]
Li, Jing [1 ,2 ]
Kim, Dong Shoo [1 ,2 ]
Kim, Jung-Lye [1 ,2 ]
Shin, Seung-Yong [1 ,2 ]
Lee, Yong-Jin [3 ]
Kwun, In-Sook [4 ]
Kang, Young-Hee [1 ,2 ]
机构
[1] Hallym Univ, Dept Food & Nutr, Chunchon 200702, Kangwon Do, South Korea
[2] Hallym Univ, Korean Inst Nutr, Chunchon 200702, Kangwon Do, South Korea
[3] Chuncheon Bioind Fdn, Chunchon 200702, Kangwon Do, South Korea
[4] Andong Univ, Andong 760749, Kyeongsangbuk, South Korea
关键词
Angiogenesis; Isoliquiritigenin; MMP-2; MT MMP-1; PMA; Tube formation; PROSTATE-CANCER CELLS; GLYCYRRHIZA-GLABRA; TUMOR-GROWTH; DOWN-REGULATION; IN-VITRO; EXPRESSION; APOPTOSIS; METASTASIS; CARCINOMA; SURVIVAL;
D O I
10.1016/j.jnutbio.2008.10.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aberrant expression of matrix metalloproteinases (MMPs) has been implicated in matrix degradation leading to angiogenesis. This study examined the inhibitory effects of isoliquiritigenin (ISL) on phorbol myristate acetate (PMA)-induced MMP production and its tissue inhibitor of MMP (TIMP) in endothelial cells. No induction of either necrotic or apoptotic cell death was observed in response to a treatment with ISL at <= 25 mu M. ISL dose-dependently suppressed PMA-induced expression and activity of MMP-2 and membrane type 1-MMP at >= 1 mu M while diminishing the elevated MMP-2 transcript level. In addition, ISL inhibited PMA-triggered migration and tube formation in a dose-dependent manner. ISL further increased the TIMP production up-regulated by PMA with a biphasic effect on TIMP-2 expression. This study further attempted to investigate whether a c-Jun N-terminal kinase (JNK)- or p38 mitogen-activated protein kinase (MAPK)-responsive mechanism was responsible for the MMP production and whether ISL disturbed these signaling pathways. PMA stimulated signaling of JNK and p38 MAPK, which was dampened by >= 10 mu M ISL. These results demonstrate that ISL blocked JNK- or p38 MAPK-responsive pathways leading to direct MMP activation of PMA-exposed endothelial cells. Therefore, the ISL inhibition of MMP may boost a therapeutic efficacy during angiogenesis. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:55 / 65
页数:11
相关论文
共 35 条
  • [11] Flavanone and 2′-OH flavanone inhibit metastasis of lung cancer cells via down-regulation of proteinases activities and MAPK pathway
    Hsiao, Yung-Chin
    Kuo, Wu-Hsien
    Chen, Pei-Ni
    Chang, Horng-Rong
    Lin, Tseng-Hsi
    Yang, Wei-En
    Hsieh, Yih-Shou
    Chu, Shu-Chen
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2007, 167 (03) : 193 - 206
  • [12] John Anitha, 2001, Pathology and Oncology Research, V7, P14
  • [13] Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells
    Jung, Jae In
    Chung, Eunkyung
    Seon, Mi Ra
    Shin, Hyun-Kyung
    Kim, Eun Ji
    Lim, Soon Sung
    Chung, Won-Yoon
    Park, Kwang-Kyun
    Park, Jung Han Yoon
    [J]. BIOFACTORS, 2006, 28 (3-4) : 159 - 168
  • [14] Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells
    Jung, Jae In
    Lim, Soon Sung
    Choi, Hyun Ju
    Cho, Han Jin
    Shin, Hyun-Kyung
    Kim, Eun Ji
    Chung, Won-Yoon
    Park, Kwang-Kyun
    Park, Jung Han Yoon
    [J]. JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2006, 17 (10) : 689 - 696
  • [15] Glabridin, an isoflavan from licorice root, inhibits inducible nitric-oxide synthase expression and improves survival of mice in experimental model of septic shock
    Kang, JS
    Yoon, YD
    Cho, IJ
    Han, MH
    Lee, CW
    Park, SK
    Kim, HM
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (03) : 1187 - 1194
  • [16] A role for endothelial-derived matrix metalloproteinase-2 in breast cancer cell transmigration across the endothelial-basement membrane barrier
    Kargozaran, Hamed
    Yuan, Sarah Y.
    Breslin, Jerome W.
    Watson, Katherine D.
    Gaudreault, Nathalie
    Breen, Alison
    Wu, Mack H.
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2007, 24 (07) : 495 - 502
  • [17] Katiyar Santosh K., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P17
  • [18] KOBAYASHI S, 1995, BIOL PHARM BULL, V18, P1382, DOI 10.1248/bpb.18.1382
  • [19] Kugler A, 1999, ANTICANCER RES, V19, P1589
  • [20] Kwon HM, 2007, EXP BIOL MED, V232, P235